multiplylabs.com

• Cellular Origins: It competes on a similar architecture, integrating validated instruments with configurable robotics. Its step-specific expansion and mobile robots may fit uneven bottlenecks better than duplicating whole clusters. Its claimed 51% COGS reduction and approximately 11-month payback come from modeling, not guaranteed customer outcomes. Its 2026 brochure says the first system was delivered in early 2025 and a first GMP installation was scheduled for 2026. (cellularorigins.com)
• Cellares: This option aligns with sponsors seeking manufacturing capacity without operating their own factory. Its disclosed stack combines Cell Shuttle manufacturing, Cell Q testing, and an IDMO service network. Its claimed productivity and pricing advantages require contractual and process-specific verification. (cellares.com)
• Miltenyi: This option may fit workflows suited to an integrated platform where familiar training and support are priorities. Its website reports more than 300 custom workflows and use in more than 150 clinical trials; these are vendor-reported adoption figures, not independently audited market share. (miltenyibiotec.com)
• Lonza Cocoon: This is an alternative closed, automated instrument approach. Buyers should compare workflow coverage, disposables, scale-out requirements, and support—not assume it has the same factory-level architecture as Multiply Labs. (dam.lonza.com)
• Ori Biotech: This is an alternative purpose-built process platform. Its October 6, 2026 Catalent announcement describes access through a preferred-partner network and reports an FDA Advanced Manufacturing Technology designation. This is a different route from automating a buyer’s existing instrument chain. (oribiotech.com)

No credible market-share percentage for Multiply Labs was established. Funding, collaborations, installed instruments, and clinical-trial use are different measures and should not be combined into a ranking.

The available evidence supports competitive activity and increasing interest in automation, but not a claim that Multiply Labs leads commercial deployment. Its disclosed positioning is a specialist orchestration approach with pharmaceutical evaluation activity, rather than a verified market-share leader. (multiplylabs.com)